Thompson Rubinstein Investment Management Inc. OR held its stake in shares of CVS Health Corporation (NYSE:CVS) during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 23,222 shares of the pharmacy operator’s stock at the end of the third quarter. Thompson Rubinstein Investment Management Inc. OR’s holdings in CVS Health Corporation were worth $2,067,000 at the end of the most recent reporting period.

A number of other large investors also recently made changes to their positions in CVS. Nordea Investment Management AB increased its position in CVS Health Corporation by 61.3% in the second quarter. Nordea Investment Management AB now owns 11,644,431 shares of the pharmacy operator’s stock valued at $1,114,838,000 after buying an additional 4,423,216 shares during the period. Magellan Asset Management Ltd increased its position in CVS Health Corporation by 1.6% in the second quarter. Magellan Asset Management Ltd now owns 10,300,505 shares of the pharmacy operator’s stock valued at $986,170,000 after buying an additional 160,188 shares during the period. Dimensional Fund Advisors LP increased its position in CVS Health Corporation by 2.3% in the second quarter. Dimensional Fund Advisors LP now owns 9,278,646 shares of the pharmacy operator’s stock valued at $888,270,000 after buying an additional 205,585 shares during the period. Macquarie Group Ltd. increased its position in CVS Health Corporation by 9.7% in the second quarter. Macquarie Group Ltd. now owns 7,707,523 shares of the pharmacy operator’s stock valued at $737,919,000 after buying an additional 682,784 shares during the period. Finally, TIAA CREF Investment Management LLC increased its position in CVS Health Corporation by 0.8% in the second quarter. TIAA CREF Investment Management LLC now owns 6,819,880 shares of the pharmacy operator’s stock valued at $652,935,000 after buying an additional 51,493 shares during the period. 80.44% of the stock is currently owned by institutional investors and hedge funds.

Institutional Ownership by Quarter for CVS Health Corporation (NYSE:CVS)

CVS Health Corporation (NYSE:CVS) traded up 1.47% during trading on Tuesday, hitting $75.88. The stock had a trading volume of 8,649,575 shares. CVS Health Corporation has a 52-week low of $69.30 and a 52-week high of $106.67. The stock has a market capitalization of $80.92 billion, a PE ratio of 16.26 and a beta of 0.88. The stock’s 50-day moving average is $81.31 and its 200-day moving average is $91.35.

CVS Health Corporation (NYSE:CVS) last released its earnings results on Tuesday, November 8th. The pharmacy operator reported $1.64 earnings per share for the quarter, topping analysts’ consensus estimates of $1.57 by $0.07. CVS Health Corporation had a return on equity of 17.18% and a net margin of 2.96%. The business had revenue of $44.60 billion for the quarter, compared to analyst estimates of $45.29 billion. During the same quarter last year, the firm posted $1.28 earnings per share. The business’s revenue was up 15.5% compared to the same quarter last year. On average, analysts predict that CVS Health Corporation will post $5.81 earnings per share for the current fiscal year.

The firm also recently announced a quarterly dividend, which was paid on Thursday, November 3rd. Shareholders of record on Monday, October 24th were paid a $0.425 dividend. The ex-dividend date of this dividend was Thursday, October 20th. This represents a $1.70 dividend on an annualized basis and a yield of 2.24%. CVS Health Corporation’s payout ratio is 36.40%.

ILLEGAL ACTIVITY WARNING: This piece was reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this piece on another domain, it was illegally copied and republished in violation of U.S. & international trademark & copyright legislation. The correct version of this piece can be accessed at https://www.thecerbatgem.com/2016/11/29/thompson-rubinstein-investment-management-inc-or-maintains-position-in-cvs-health-corporation-cvs.html.

Several research analysts have recently issued reports on the stock. Argus restated a “buy” rating and issued a $85.00 target price (down previously from $120.00) on shares of CVS Health Corporation in a report on Thursday, November 10th. Barclays PLC restated a “buy” rating and issued a $85.00 target price on shares of CVS Health Corporation in a report on Wednesday, November 9th. Leerink Swann restated a “buy” rating and issued a $105.00 target price on shares of CVS Health Corporation in a report on Wednesday, November 9th. Mizuho raised their target price on shares of CVS Health Corporation from $90.00 to $111.00 and gave the stock a “buy” rating in a report on Wednesday, November 9th. Finally, Guggenheim restated a “buy” rating and issued a $90.00 target price (down previously from $115.00) on shares of CVS Health Corporation in a report on Tuesday, November 8th. Five analysts have rated the stock with a hold rating, thirteen have given a buy rating and one has given a strong buy rating to the stock. CVS Health Corporation presently has a consensus rating of “Buy” and a consensus target price of $106.24.

CVS Health Corporation Company Profile

CVS Health Corporation, together with its subsidiaries (CVS Health), is a pharmacy company. The Company operates through three business segments: Pharmacy Services, Retail/LTC and Corporate. The Company offers a range of products and services, such as advising patients on their medications at its CVS Pharmacy locations, introducing programs to help control costs for its clients at CVS Caremark, how care is delivered to its patients with conditions through CVS Specialty, pharmacy care for the senior community through Omnicare.

5 Day Chart for NYSE:CVS

Receive News & Stock Ratings for CVS Health Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CVS Health Corporation and related stocks with our FREE daily email newsletter.